Comparative Study of Safety and Efficacy of Angiotensin-Receptor Blockers and Anti Amyloid-ß Monoclonal Antibodies for the Treatment of Alzheimer's Disease: A Systematic Review.

Autor:	Shahid K; Internal Medicine/Family Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Tamene Y; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Mody SP; Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Sadiq KO; General Surgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Shivakumar YM; Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Burra E; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Ramphall S; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Aug 23; Vol. 15 (8), pp. e43984. Date of Electronic Publication: 2023 Aug 23 (Print Publication: 2023).
DOI:	10.7759/cureus.43984
Abstrakt:	Amyloid-ß (Aß) plaques and Neurofibrillary tangles are hallmarks of Alzheimer's disease (AD) pathology. Recent advances to find a cure for AD have led to the exploration of Anti-Aß monoclonal antibodies and angiotensin-receptor blockers (ARBs). The antibodies can decrease plaque formation or remove already formed plaques. ARBs increase angiotensin II (AT2) levels and decrease the effect of AT2 on the AT1 receptor (AT1R). This systematic analysis reviews evidence of monoclonal antibodies (Aducanumab, Lecanemab, Donanemab, and Solanezumab) and ARBs in managing AD. An in-depth methodical search was conducted across PubMed, Science Direct, and Mendeley. PRISMA 2020 guidelines were followed for this study. Randomized control trials for antibodies and ARBs and one retrospective cohort study were included. The comparison was made among studies that shared similar measured outcomes. Antibodies were found to be more effective than ARBs, with Aducanumab and Lecanemab being the most effective. ARBs, on the other hand, were found to be the safer choice. Further trials of longer duration and larger sample sizes are needed to explore both groups' long-term safety and efficacy. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Shahid et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu